Assessment of therapy response to Regorafenib by 18 F-DOPA-PET/CT in patients with recurrent high-grade gliomas: a case series
DiscussionThese preliminary findings suggest that18F-DOPA PET/CT allows an early and reliable assessment of metabolic response to the REG treatment. A major advantage of PET seems to be obtained in patients in whom MR is unable to differentiate non-response vs tumor pseudo-progression.
CONCLUSION: 3D ASL and DSC PWI are consistent in evaluating blood flow in brain tumors and can accurately evaluate brain tumors perfusion.PMID:34549723 | DOI:10.12122/j.issn.1673-4254.2021.08.23
ConclusionTumor isocontour T-maps and combined analysis of CBF and [18F]DOPA-PET uptake allow achieving high diagnostic performance in differentiating between progression and pseudo-progression in treated gliomas. The sensitivity is particularly high for glioblastomas.Key Points•Applied separately, MRI and PET imaging modalities may be insufficient to characterize the brain glioma post-therapeutic profile.•Combined ASL and [18F]DOPA-PET map analysis allows differentiating between tumor progression and pseudo-progression.
We investigated the correlation between amide proton transfer-weighted magnetic resonance imaging (APTw MRI) and dynamic susceptibility contrast (DSC) perfusion in order to assess the potential of APTw MRI as an alternative to DSC in adult brain tumor (glioma) imaging.
Conclusions The combination of multiple MR parameters evaluated together with 18F-DOPA PET offers an attractive approach to noninvasively distinguish true recurrence from radiation necrosis. However, further prospective studies with larger cohorts are warranted with additional neuropathological validations.